Urocortin-deficient mice and uses thereof

Details Urocortin-deficient mice and uses thereof Urocortin-deficient mice and uses thereof

2003-05-19

2009-02-10

Falk, Anne-Marie (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S013000

Reexamination Certificate

active

07488865

ABSTRACT:
The present invention provides transgenic mice deficient in urocortin. Urocortin null mutant mice are hypersensitive to stress and display heightened anxiety-like behaviors in the elevated plus maze and open field tests. These mice also demonstrate physiological alterations in auditory thresholds and distortion product otoacoustic emissions. These results indicate that urocortin plays a modulatory role in anxiety-related behaviors and in contributing to the establishment of auditory thresholds. Such urocortin deficient mutant mice can provide useful models in the study of anxiety pathology and hearing physiology at the biochemical and molecular levels.

REFERENCES:
patent: 6147275 (2000-11-01), Vale et al.
patent: 6353152 (2002-03-01), Lee et al.
Doetschman, T. (1999) Interpretation of phenotype in genetically engineered mice. Laboratory Animal Science 49(2): 137-143.
Donehower et al. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Molecular Carcinogenesis 14: 16-22.
Jacks et al. (1992) Effects of an Rb mutation in the mouse. Nature 359: 295-300.
Jaenisch et al. (1988) Transgenic Animals. Science 240: 1468-1474.
Kuehn et al. (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326: 295-298.
Moens et al. (1993) Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. Development 119: 485-499.
Petridou et al. (2003) Heterogeneous inducible mammary-specific expression of JAB/SOCS1 in lactating transgenic mice is associated with no obvious phenotype, even at the cellular level. Transgenic Research 12: 693-706.
Sigmund, CD (2000) Viewpoint: Are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20: 1425-1429.
Wang et al. (Sep. 2002) Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Molecular and Cellular Biology 22(18): 6605-6610.
JAX Mice Price List (Jun. 1997) F1 Hybrids, p. 22.
Bale et al., “Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress,”Nat. Genet., 24:410-414, 2000.
Bale et al., “Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior,” J. Neurosci., 22:193-199, 2002.
Coste et al., “Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2,”Nat. Genet., 24:403-409, 2000.
Cullen et al., “Urocortin, corticotropin releasing factor-2 receptors and energy balance,”Endocrinology, 142:992-999, 2001.
Kishimoto et al., “Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2,”Nat. Genet., 24:415-419, 2000.
Kihara et al., “Effects of central and peripheral urocortin on fed and fasted gastroduodenal motor activity in conscious rats,”Am J Physiol Gastrointest Liver Physiol., 280:G406-G419, 2001.
Moreau et al., “Urocortin, a novel neuropeptide with anxiogenic-like properties,”Neuroreport, 8:1697-1701, 1997.
Perrin et al., “Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors,”J. Pharacol. Exp. Therapeutics, 288:729-734, 1999.
Schilling et al., “Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery,”Brit. J. Pharamol., 125:1164-1171, 1998.
Slawecki, et al., “Neurophysiological effects of intracerebroventricular administration of urocortin,”Peptides, 20:211-218, 1999.
Smagin et al., “The role of CRF2 receptors in corticotropin-releasing factor- and urocortin- induced anorexia,”Neuroreport, 9:1601-1606, 1998.
Smith et al., “Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development,”Neuron, 20(6):1093-1102.
Spina et al., “Appetite-suppressing effects of urocortin, a CRF-related neuropeptide,”Science, 273:1561-1564, 1996.
Weninger et al., “Urocortin expression in the Edinger-Westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency,”Endocrinology, 141:256-263, 2000.
Smith et al., “Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development,”Neuron, 20(6):1093-1102, 1998.

Affiliated with

Also associated with

Rating

Urocortin-deficient mice and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Urocortin-deficient mice and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urocortin-deficient mice and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4137440